SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Isotechnika
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: schzammm who wrote (63)5/26/2003 11:55:10 AM
From: Icebrg  Read Replies (1) of 285
 
>> Plenty of competition in the psoriasis market>>

Yes, there is a lot. But the table doesn't appear to be completely up to date. Some of these drugs have already been discontinued.

Provided that ISA247 can repeat their plaque clearing results from phase II and maintain its very good safety profile (that's at least what the company likes to implicate) it should have a number of big advantages. Provided and if that is.

1. It is an oral drug.
Provides a big benefit when compared for example with the biologics which have to be administered by injection. What do most people prefer? A pill or an Sub-Q injection? And at least Amevive has to be given IV. A visit to the doctor's office will be required every time.

2. It has high efficacy.
The clearance rates as they have been reported are up there with the very best.

3. It will not be very expensive.
That is at least what I suppose. Small molecule drugs have a great advantage compared with the biologics.

4. It has a supporter carrying a big name and a big organisation.

5. It is a known entity. Everyone dealing with autoimmune disease knows cyclosporin. It has high efficacy and bad side-effects. Cyclosporin Mk II will be a step ahead of most of its competitors. As long as they can convincingly show that the efficacy remains and the safety concerns have disappeared. But they will have to prove it. Beyond any doubts.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News